Stock comparison
Novartis AG is 380.1x more valuable than MoonLake Immunotherapeutics by market capitalization ($309.21 B vs $813.45 M). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
NVS is larger
Novartis AG is 380.1x more valuable than MoonLake Immunotherapeutics by market capitalization ($309.21 B vs $813.45 M).
Market value leader
NVS
Novartis AG is 380.1x more valuable than MoonLake Immunotherapeutics by market capitalization ($309.21 B vs $813.45 M).
| Metric | MLTX | NVS |
|---|---|---|
| Market cap | $813.45 M | $309.21 B |
| US-listed rank | #2584 | #38 |
| Net income (latest FY) | -$227.32M | - |
| Net margin | - | - |
| P/E (trailing FY) | - | - |
| SEC filings | 296 | 953 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Novartis AG is 380.1x more valuable than MoonLake Immunotherapeutics by market capitalization ($309.21 B vs $813.45 M).
Full pages: MoonLake Immunotherapeutics and Novartis AG, or browse the full rankings.